Modulation of immune system with .DELTA.5-androstenes
US5292730A · kind A · utility
33Cited by
1References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 31, 1992 |
| Grant date | Mar 8, 1994 |
| Priority date | — |
| Expiry date | Jul 31, 2012 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Alzheimer's disease and immune deficiency disorders may be effectively treated by administering a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.by administering a therapeutic amount of a .DELTA.5-Androstene-3.beta.-ol-17-one having a C.sub.7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.